<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="237256">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004380</url>
  </required_header>
  <id_info>
    <org_study_id>199/12015</org_study_id>
    <secondary_id>SUMC-37488</secondary_id>
    <nct_id>NCT00004380</nct_id>
  </id_info>
  <brief_title>Phase II Study of Recombinant Relaxin for Progressive Systemic Sclerosis</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Center for Research Resources (NCRR)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Office of Rare Diseases (ORD)</source>
  <brief_summary>
    <textblock>
      OBJECTIVES: I. Determine whether parenteral relaxin improves skin tightness, Raynaud's
      phenomenon, digital morbidity, and digital ulcers in a patient with progressive systemic
      sclerosis (scleroderma).

      II. Determine whether relaxin decreases collagen production by fibroblasts in vivo and
      cultured from skin biopsies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PROTOCOL OUTLINE: This is a compassionate use study. The patient is treated with
      subcutaneous injections of recombinant relaxin for approximately 12 months. If clinically
      indicated, therapy may be extended.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 1991</start_date>
  <completion_date>December 1997</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment>1</enrollment>
  <condition>Systemic Sclerosis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>relaxin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        PROTOCOL ENTRY CRITERIA:

        --Disease Characteristics--

          -  Progressive systemic sclerosis (scleroderma)

          -  No pregnant or nursing women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>G. Scott Herron</last_name>
    <role>Study Chair</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <verification_date>July 2004</verification_date>
  <lastchanged_date>June 23, 2005</lastchanged_date>
  <firstreceived_date>October 18, 1999</firstreceived_date>
  <keyword>arthritis &amp; connective tissue diseases</keyword>
  <keyword>rare disease</keyword>
  <keyword>systemic sclerosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Scleroderma, Systemic</mesh_term>
    <mesh_term>Scleroderma, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Methocarbamol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
